Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Replicative cycle of HIV
3. HIV reverse transcriptase (1)
4. Nucleoside reverse transcriptase inhibitors
5. HIV reverse transcriptase (2)
6. Zidovudine
7. Original paper describing zidovudine
8. Didanosine
9. Zalcitabine
10. Stavudine
11. Original paper describing stavudine (1)
12. Original paper describing stavudine (2)
13. Lamivudine
14. Abacavir
15. Emtricitabine
16. Mechanism of action of AZT
17. Nucleotide reverse transcriptase inhibitors
18. Tenofovir
19. Original paper describing Tenofovir
20. Mechanism of action of Tenofovir
21. Non-nucleoside reverse transcriptase inhibitors
22. HIV reverse transcriptase (3)
23. The first NNRTI
24. Tivirapine/Emivirine
25. Nevirapine
26. Delavirdine
27. Efavirenz
28. Etravirine
29. HIV RT complexed with DNA template primer
30. Superposition of nevirapine and TMC125
31. TMC125 positioned in HIV-RT NNRTI-binding site
32. Rilpivirine
33. Molecular modeling of rilpivirine
34. Protease inhibitors
35. Protease inhibitors' mode of action
36. Saquinavir
37. Ritonavir
38. Indinavir
39. Nelfinavir
40. Amprenavir
41. Lopinavir
42. Atazanavir
43. Fosamprenavir
44. Tipranavir
45. Darunavir
46. Hydroxyethylene bond
47. HIV protease structure with PI in active site
48. Fusion inhibitors
49. Enfuvirtide
50. Enfuvirtide structure
51. Mechanism of action of enfuvirtide
52. Co-receptor inhibitors
53. Maraviroc
54. Vicriviroc
55. Mechanism of action of co-receptor antagonists
56. AMD3100
57. Indication for the clinical use of AMD3100
58. The AMD3100 story
59. Integrase inhibitors
60. Raltegravir
61. The two integrase catalytic reactions
62. Elvitegravir
63. Highly active antiretroviral therapy
64. Drug combinations
65. Evolution of fixed-dose combinations
66. Drug evolution
67. Acyclic nucleoside phosphonates
68. (S)-HPMPA
69. Prodrug of tenofovir
70. Tenofovir disoproxil fumarate (TDF)
71. Truvada
72. Atripla
73. Tenofovir DF and Emtricitabine-the top two drugs
74. U.S. HIV market dynamics
75. Tenofovir DF transformed HIV treatment
76. HIV treatment in the developing world
77. Number of patients treated, U.S.
78. U.S. HIV patient share
79. U.S. market share: HBV prescriptions
80. GS 7340: dose response vs. Viread
81. GS 7340: targeting lymphoid cells
82. Future fixed-dose drug combination pill
83. Forthcoming fixed-dose combinations
84. Near term TDF single tablet regimens
85. Chronic suppressive therapy limitations
86. Prophylaxis
87. Milestones in the development of tenofovir
88. TDF in the prophylaxis of HIV infections
89. Trials to test pre-exposure prophylaxis
90. The CAPRISA 004 study
91. Tenofovir gel reduced HIV acquisition
92. Probability of HIV infection with tenofovir gel
93. Chemoprophylaxis for HIV prevention (1)
94. Chemoprophylaxis for HIV prevention (2)
95. A showcase of compounds developed in IOCB
96. Antonin Holy
97. The 3 disciplines

Topics Covered

• Targets for anti-HIV therapy
• Reverse transcriptase
• Nucleoside reverse transcriptase inhibitors
• Nucleotide reverse transcriptase inhibitors
• Non-nucleoside reverse transcriptase inhibitors
• Protease inhibitors
• Fusion inhibitors
• Co-receptor inhibitors
• Integrase inhibitors
• Anti-HIV drug combinations
• Prophylaxis of HIV infections

Links

Series:

• Antivirals

Categories:

• Clinical Practice
• Microbiology
• Pharmaceutical Sciences

Therapeutic Areas:

• Infectious Diseases

Talk Citation

Publication History

• Published on August 30, 2011

Financial Disclosures

• Prof. Dr. Erik De Clercq has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.